4D Molecular Therapeutics Inc Interim Clinical Data Presented at NACFC - Corporate Call Transcript
Hello, ladies and gentlemen. Thank you for standing by, and welcome to the 4D Molecular Therapeutics 4D-710 Phase I/II Interim Clinical Data Conference Call. (Operator Instructions) As a reminder, today's call is being recorded.
With that, I will hand the call over to August Moretti, Chief Financial Officer, who will make introductory comments.
Thank you, operator, and welcome, everyone, to 4D Molecular Therapeutics 4D-710 Phase I/II Interim Clinical Data Conference Call. With me today are Dr. David Kirn, our Co-Founder and Chief Executive Officer; and Dr. Robert Fishman, our Chief Medical Officer and Pulmonology Therapeutic Area Head.
As a reminder, on this call, we will be making forward-looking statements regarding our clinical data from our 4D-710 Phase I/II clinical trial, product development plans and research activities. These statements are subject to risks and uncertainties that may cause actual results to materially differ from those forecasted. A description of these risk
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |